SYN117 (nepicastat) + Placebo comparator

Phase 2Withdrawn
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Traumatic Stress Disorder (PTSD)

Conditions

Post Traumatic Stress Disorder (PTSD)

Trial Timeline

Jun 1, 2008 → Nov 1, 2009

About SYN117 (nepicastat) + Placebo comparator

SYN117 (nepicastat) + Placebo comparator is a phase 2 stage product being developed by Johnson & Johnson for Post Traumatic Stress Disorder (PTSD). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00641511. Target conditions include Post Traumatic Stress Disorder (PTSD).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00641511Phase 2Withdrawn

Competing Products

20 competing products in Post Traumatic Stress Disorder (PTSD)

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
PRF110PainReformPhase 2
44
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
Placebo + DS-5565Daiichi SankyoPre-clinical
23
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
77
QUTENZAAstellas PharmaApproved
85
QutenzaAstellas PharmaPre-clinical
23
CelecoxibAstellas PharmaPre-clinical
23
ASP8477 + PlaceboAstellas PharmaPhase 2
52